NasdaqCM:DCTHMedical Equipment
A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT
Delcath Systems (DCTH) is back in focus after publishing detailed subgroup analyses from its phase 3 FOCUS study on HEPZATO KIT in unresectable metastatic uveal melanoma, helping refine how clinicians view efficacy and safety across different patient groups.
See our latest analysis for Delcath Systems.
The publication arrives after a mixed stretch for Delcath Systems, with a 30 day share price return of 6.85% and a 90 day share price return decline of 5.86%. The 3 year total shareholder...